Iscalimab
Iscalimab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against tumor necrosis factor receptor superfamily member 5.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | — | 2 | — | — | — | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | — | 1 |
| Hidradenitis suppurativa | D017497 | L73.2 | — | 1 | — | — | — | 1 | |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | 1 | — | — | — | 1 |
| Lupus nephritis | D008181 | EFO_0005761 | — | 1 | — | — | — | 1 | |
| Graves disease | D006111 | EFO_0004237 | E05.0 | — | 1 | — | — | — | 1 |
| Myasthenia gravis | D009157 | EFO_0004991 | G70.0 | — | 1 | — | — | — | 1 |
| Kidney transplantation | D016030 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ISCALIMAB |
| INN | iscalimab |
| Description | Iscalimab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against tumor necrosis factor receptor superfamily member 5. |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298210 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 0628T707D0 (ChemIDplus, GSRS) |
Target
Agency Approved
CD40
CD40
Organism
Homo sapiens
Gene name
CD40
Gene synonyms
TNFRSF5
NCBI Gene ID
Protein name
tumor necrosis factor receptor superfamily member 5
Protein synonyms
B cell surface antigen CD40, B cell-associated molecule, B-cell surface antigen CD40, Bp50, CD40, CD40 molecule, TNF receptor superfamily member 5, CD40L receptor, CDw40
Uniprot ID
Mouse ortholog
Cd40 (21939)
tumor necrosis factor receptor superfamily member 5 (Q99NE3)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 117 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
84 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more